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Abstract: BACKGROUND Continuous delivery to the jejunum of levodopa-carbidopa is a promising
therapy in patients with advanced Parkinson’s disease, as it reduces motor fluctuation. Percutaneous en-
doscopic gastrostomy and jejunal tube (PEG-J) placement is a suitable option for this. However, studies
focused in PEG-J management are lacking. OBJECTIVES We report our experience regarding this tech-
nique, including technical success, adverse events and outcomes, in patients with advanced Parkinson’s
disease. METHODS Twenty-seven advanced Parkinson’s disease patients (17 men, median age: 64 years,
median disease duration: 11 years) were included in a retrospective study from June 2007 to April 2015.
The median follow-up period was 48 months (1-96). RESULTS No adverse events were noted during
and after nasojejunal tube insertion (to assess treatment efficacy). After a good therapeutic response, a
PEG-J was placed successfully in all patients. The PEG tube was inserted according to Ponsky’s method.
The jejunal extension was inserted during the same procedure in all patients. Twelve patients (44%) ex-
perienced severe adverse events related to the PEG-J insertion, which occurred after a median follow-up
of 15.5 months. Endoscopy was the main treatment modality. Patients who experienced severe adverse
events had a higher comorbidity score (p = 0.011) but were not older (p = 0.941) than patients who did
not. CONCLUSIONS While all patients responded well to levodopa-carbidopa regarding neurological
outcomes, gastro-intestinal severe adverse events were frequent and related to comorbidities. Endoscopic
treatment is the cornerstone for management of PEG-J related events. In conclusion, clinicians and en-
doscopists, as well as patients, should be fully informed of procedure-related adverse events and patients
should be followed in centres experienced in their management.
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Abstract
Background: Continuous delivery to the jejunum of levodopa-carbidopa is a promising therapy in patients with advanced
Parkinson’s disease, as it reduces motor fluctuation. Percutaneous endoscopic gastrostomy and jejunal tube (PEG-J) place-
ment is a suitable option for this. However, studies focused in PEG-J management are lacking.
Objectives: We report our experience regarding this technique, including technical success, adverse events and outcomes, in
patients with advanced Parkinson’s disease.
Methods: Twenty-seven advanced Parkinson’s disease patients (17 men, median age: 64 years, median disease duration:
11 years) were included in a retrospective study from June 2007 to April 2015. The median follow-up period was 48 months
(1–96).
Results: No adverse events were noted during and after nasojejunal tube insertion (to assess treatment efficacy). After a
good therapeutic response, a PEG-J was placed successfully in all patients. The PEG tube was inserted according to Ponsky’s
method. The jejunal extension was inserted during the same procedure in all patients. Twelve patients (44%) experienced
severe adverse events related to the PEG-J insertion, which occurred after a median follow-up of 15.5 months. Endoscopy
was the main treatment modality. Patients who experienced severe adverse events had a higher comorbidity score
(p¼ 0.011) but were not older (p¼ 0.941) than patients who did not.
Conclusions: While all patients responded well to levodopa-carbidopa regarding neurological outcomes, gastro-intestinal
severe adverse events were frequent and related to comorbidities. Endoscopic treatment is the cornerstone for management
of PEG-J related events. In conclusion, clinicians and endoscopists, as well as patients, should be fully informed of
procedure-related adverse events and patients should be followed in centres experienced in their management.
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Introduction
Parkinson’s disease is a neurodegenerative disorder
resulting from the death of dopamine neurons in the
substantia nigra pars compacta with resultant depletion
of striatal dopamine leading to motor, behavioural
and/or cognitive symptoms.1
Levodopa, the precursor of dopamine, is the gold
standard treatment. However, chronic oral levodopa
is associated with complications such as motor fluctu-
ations (on- and off-time), including dyskinesia during
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the on-time.1 This is due to fluctuating levodopa
plasma concentrations resulting from levodopa’s short
half-life, delayed gastric emptying and diet-related
competition for jejunal uptake mechanisms.2 Today,
continuous delivery of levodopa with carbidopa (a
decarboxylase inhibitor) into the jejunum represents
one of the best alternatives for advanced Parkinson’s
disease patients as it avoids motor fluctuations (on- and
off-time) and dyskinesia.1 Enteral access with percutan-
eous endoscopic gastrostomy and jejunal tube (PEG-J)
placement is the most commonly performed method to
uninterruptedly deliver levodopa-carbidopa.1,3
Considering the effectiveness and success of this
novel therapeutic modality, PEG-J placement for this
indication will soon be routine for many endoscopists.1
Thus, PEG-J insertion techniques, occurrence and
management of adverse events should be studied in
detail, regarding this particular patient group.
Currently available data about adverse events
experienced by patients receiving enteral levodopa-car-
bidopa do not focus on modalities regarding PEG-J
insertion but, nevertheless, report that the majority of
adverse events (63%) are related to the infusion
system.3,4 In fact, series focused on insertion, adverse
events and management of the PEG-J, from an endos-
copist point of view, for this particular indication, are
scarce.5 Up to now, modalities of PEG-J placement and
PEG-J related management of adverse events rely
mainly on expert opinion.6
The Belgian levodopa multicentric prospective
study assessed the intestinal levodopa-carbidopa effi-
cacy, from a neurologist point of view.7 During this
trial, we also collected data concerning PEG-J manage-
ment in our academic institution. We conducted a
retrospective study in which insertion technical modal-
ities, short- and long-term clinical outcomes and
adverse event occurrence and management were ana-
lysed and put in line with a comorbidity scoring to




An observational retrospective study assessing effect-
iveness and safety of PEG-J insertion for continuous
levodopa-carbidopa intestinal gel (LCIG, Duodopa,
AbbVie, Wavre, Belgium) infusion was conducted as
part of the Belgian levodopa multicentric study7
between June 2007 and April 2015. Patients recruited
from our centre were considered for the present analysis
(Figure 1). Inclusion required meeting the levodopa-
carbidopa Belgian reimbursement criteria7 regarding
Parkinson’s disease, including neurological
improvement after a test dose administered through a
nasojejunal tube. The protocol was submitted to and
approved by the Erasme University Hospital review
board and ethics committee. Patients or their legal rep-
resentatives gave written informed consent for partici-
pation in the trial.
Endoscopic procedures and protocol
Initially, a nasojejunal tube (Freka Endolumina
Nasojejunal Feeding Tube CH8; Bad Homburg,
Germany) was inserted in all patients to assess levo-
dopa-carbidopa efficiency and dosage, for a minimal
period of four days. The PEG-J was used exclusively
for levodopa-carbidopa infusion. The nasojejunal tube
was placed either by a transnasal route with the use of a
paediatric scope (GIFXP180N, Olympus, Hamburg,
Germany) or transorally with a standard gastroscope
(GIF-Q160, GIF-H180, GIF-H190; Olympus,
Hamburg, Germany). The PEG-J tube was placed
during a second endoscopic procedure only after obser-
vation of a good response to intestinal continuous infu-
sion of levodopa-carbidopa during clinical evaluation,
which was performed by a neurologist. Both PEG and
jejunal extension were placed during this second endo-
scopic procedure.
The PEG-J (Freka PEG CH15, and Freka CH9
Intestinal Tube for CH15 PEG; Bad Homburg,
Germany) was placed under general anaesthesia
with tracheal intubation in all patients, in order to
minimize immediate adverse event occurrence.8
Antibioprophylaxis consisted in a single dose of
cefazolin (2 g) or amoxicillin/clavulanic acid (2 g). The
PEG tube was inserted according to the ‘Ponsky pull’
technique9 using a standard adult gastroscope
(GIF-Q160, GIF-H180, GIF-H190; Olympus,
Hamburg, Germany). The jejunal extension (Freka
CH9 Intestinal Tube for CH15 PEG; Bad Homburg,
Germany) is a radio-opaque polyurethane jejunostomy
tube designed for use with a CH15 PEG for long-term
feeding. It has a distal double S-bend with an olive tip
and small antenna tube. It was inserted during the same
procedure in all patients, by grasping the antenna tube
of the extension with a snare and dragging it up to the
distal duodenum. It is suggested that the jejunal exten-
sion design will encourage anterograde progression and
hinder intragastric retrograde migration. This
manoeuvre was performed under fluoroscopy guidance.
A 24 h fasting period followed PEG-J insertion.
PEG-J tubes were replaced after two years or earlier
if required (Supplementary Material Video 1).
Neurology follow-up visits were performed to optimize
medication dosage and to evaluate efficacy and safety.7
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Definitions
We report the results regarding endoscopic manage-
ment: modality and technical success of the endoscopic
procedures, adverse events, aftercare, follow-up regard-
ing tube replacement, and outcomes. Severe adverse
events (SAEs) were defined as those which required
specific treatment (surgery, endoscopy) and/or add-
itional hospitalization. Other adverse events were
defined as those that could be managed in the out-
patient setting and did not require additional treatment
(surgery, endoscopy), nor additional hospitalization.
Immediate adverse events were those occurring within
24 h after PEG-J placement or replacement.
Patients were followed up until their last visit, defini-
tive levodopa-carbidopa therapy interruption with
PEG-J retrieval, or death.
Comorbidities
To evaluate impact of comorbidities on outcomes, in
this relatively homogenous population of Parkinson’s
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Patients still on levodopa-carbidopa treatment (N=25)
Patients still on levodopa-carbidopa treatment at the end of the studied period (N=19)
Lost to FU (N=2)
PEG-J removals because of
congnitive impairment (N=3)
Figure 1. Flowchart of study population.
N: number of patients; FU: follow-up; PEG-J: percutaneous endoscopic gastrostomy and jejunal tube
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disease patients, we performed comorbidity scoring.
We used a recent and simple scoring system,
Comorbidity–Polypharmacy Score (CPS), which
has been validated as an independent predictor of all-
cause morbidity and mortality in older
trauma patients.10 CPS is defined as the number of
medications plus comorbidities. We also used the
Charlson Comorbidity Index (CCI), which is known
to provide a simple and valid method of estimating
risk of death from comorbid diseases for use in longi-
tudinal studies.11 These scores were calculated for each
included patient at the time of the nasojejunal tube
placement.
Statistical analysis
Data were collected and analysed using IBM SPSS stat-
istics software for Macintosh version 24 (IBM Corp.,
Armonk, New York, USA). Continuous variables were
expressed in median, maximal and minimal values.
Categorical variables were expressed in percentage.
Non-parametric tests (Mann–Whitney U test) were
used for comparison. Chi-squared test was used only
if each level of the categorical variable had an expected
frequency count of at least 5. If necessary, the Pearson
exact test was used instead. All p values reported are




Thirty-seven patients were included in the multicentre
trial7 and had PEG-J insertion for levodopa-carbidopa
infusion. Information was gathered for the 27 patients
(10 women, 17 men) who were included from our centre
between June 2007 and April 2015 (Figure 1). Median
age was 64 (42–80) years old and median disease dur-
ation was 11 (5–20) years. Regarding comorbidity,
median CCI was 0.00 (0–4) and median CPS score
was 11 (4–22) (Table 1).
Endoscopic procedures
The nasojejunal tube was inserted under sedation
(n¼ 11) or general anaesthesia (n¼ 16). This was per-
formed either from the nasal route with a paediatric
scope and the use of a guidewire (n¼ 17), or with a
standard gastroscope and a biopsy forceps (n¼ 10).
No adverse events were noted during and after nasoje-
junal tube insertion. PEG-J was inserted successfully in
all patients after a median period of 12 weeks (0.6–35)
following the nasojejunal tube placement.
Follow-up
The median follow-up duration was 48 months (1–96).
At the end of the studied period, 19 (19/27, 71%)
patients still had on-going levodopa-carbidopa therapy.
Two patients with PEG-J were lost to follow-up. One
patient died from a cause unrelated to the PEG-J inser-
tion or levodopa-carbidopa treatment. Five patients
(5/27, 19%) required PEG-J definitive removal because
of progressive cognitive impairment (n¼ 3) and gastro-
intestinal adverse events (n¼ 2, duodenal ulcer; jejunal
fistulas) (Figure 1). PEG-J withdrawal occurred after a
median follow-up duration of 14 months (1–72
months).
Regarding neurological outcome, reduction of
motor adverse events was significant, as were the
improvements in dyskinesia and motor fluctuations.7
The median number of repeat endoscopy was 2 (0–8)
(including scheduled procedures for tube replacement
and procedures for adverse event management) during
a median follow-up of 48 months (1–96 months) after
PEG-J placement.
Adverse events
After PEG-J insertion, 11 patients (11/27, 41%)
encountered immediate adverse events, including
abdominal pain (n¼ 10), general asthenia related to
anaesthesia (n¼ 1) and pneumoperitoneum (n¼ 4).
There were no immediate SAEs. Pneumoperitoneum
was diagnosed with an abdominal computed tomog-
raphy (CT) performed because of abdominal pain. In
three patients, this condition resolved spontaneously;
one was treated by needle decompression with success.
Hospitalization was not prolonged due to the above
adverse events.
Delayed adverse events were observed in 16 patients
(16/27, 59%), including 20 SAEs. Delayed minor
adverse events (n¼ 6) were observed in six patients
(6/27, 22%), including repeated but spontaneously
resolved tube occlusion (n¼ 1), gastric ulcers (n¼ 2),
duodenal ulcers (n¼ 3). Delayed SAEs (n¼ 20) were
reported in 12 patients (12/27, 44%) (Table 2).
Table 1. Characteristics of study population
Characteristics N¼ 27
Age, median (range), years 64 (42–80)
Males, n (%) 17 (63)
Time since PK diagnosis, median (range), months 132 (60–240)
CPS score, median (range) 11 (4–22)
CCI score, median (range) 0.00 (0–4)
PK: Parkinson’s disease; CPS: Comorbidity–Polypharmacy Score;
CCI: Charlson Comorbidity Index
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They included J-tube migration back towards the stom-
ach (n¼ 6), J-tube impaction in the jejunum (n¼ 1), J-
tube dysfunction (n¼ 6: leakage (n¼ 1), clogging
(n¼ 4), kinking (n¼ 1)), buried bumper syndrome
(BBS) (n¼ 2), duodenal ulcer (Figure 2) (n¼ 2), covered
duodenal perforation (Figure 3) (n¼ 1), infected intra-
abdominal collection (n¼ 1) and internal bumper
migration into the duodenum (D2) with jejunal fistulas
due to subsequent transmural jejunal tube migration
(n¼ 1) (Figure 4). SAEs occurred after a median
follow-up of 15.5 months (0.1–74 months) (Table 3)
and in a median period of 7.5 months (0.1–37) after
last PEG-J (re)placement. J-tube migration occurred
after a median period of 8.5 days (4–110) after PEG-J
last (re)placement. This latter period (between last
PEG-J (re)placement and J-tube migration) is signifi-
cantly shorter than the period between the last PEG-J
(re)placement and any other SAEs (p¼ 0.005). All
SAEs were managed successfully conservatory (n¼ 2),
by endoscopy (n¼ 17) or by surgery (n¼ 1) (Table 3).
Covered duodenal perforation (Figure 3) occurred
during an endoscopic procedure for jejunal extension
replacement, probably because of snare impaction
into the duodenal wall, and was managed conserva-
tory with antibiotics (amoxicillin/clavulanic acid, 2 g
3 times/day, i.v.). Jejunal fistulas presented with antero-
grade and transparietal migration of the jejunal tube tip
(Figure 4). This latter SAE happened 14 months after
PEG-J placement. The patient required surgical treat-
ment with intestinal resection and re-anastomosis; out-
come was favourable but PEG-J had to be definitely
removed.
Three patients (3/27, 11%) had three SAEs, two
patients (2/27, 7%) had two and seven patients (7/27,
26%) had one SAE during the follow-up. There were
no deaths related to PEG-J treatment.
Comorbidity scores and outcome
Patients who encountered SAEs during the follow-up
were not significantly older (p¼ 0.941) but had superior
comorbidity scores compared with patients who did not
encounter SAEs (p¼ 0.011). In fact, median CPS was
15 in patients who experienced SAEs compared with
10 in patients who did not. Patients who encountered
immediate adverse events had higher CPS (p¼ 0.020) in
comparison with patients who did not (Table 4). Those
patients who encountered immediate adverse events
experienced significantly more (delayed) SAEs
(p¼ 0.013) in comparison with patients who did not
encounter immediate adverse events. However,
median CCI was 1 in patients who experienced SAEs
compared with 0 in patients who did not; there was no
statistical difference (p¼ 0.105).
Neither CCI nor CPS was significantly different
between patients who encountered J-tube migration
and those who did not (respectively: p¼ 0.525,
p¼ 0.074). Still, patients who encountered migration
were significantly more confronted by other SAEs
(p¼ 0.048).
Discussion
In this study, PEG-J was successfully inserted in all
patients, confirming the technical efficiency of the
Figure 2. Stomach (a) and duodenum (b) in a patient with a trans-pyloric duodenal linear ulcer, due to traction of the jejunal tube, who
presented with abdominal pain nine months after percutaneous endoscopic gastrostomy and jejunal tube (PEG-J) insertion. This patient
required PEG-J definitive removal.








Immediate AEs 11/27 (41) < 24 h
Severe delayed AEs 12/27 (44) 15.5 (0.1–74) months
Minor delayed AEs 6/27 (22) 31 (0.1–72) months
Delayed AEs 16/27 (59) 17.5 (0.1–74) months
AE: adverse event; PEG-J: percutaneous endoscopic gastrostomy and jeju-
nal tube
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PEG-J placement method.12–14 However, the major
message of our analysis is that approximately half of
patients (44%) treated with this modality encountered
at least one SAE during a median total follow-up of 48
months. A high rate of adverse events has already been
reported in studies regarding outcome of PEG-J
inserted for enteral nutrition in malnourished patients
to prevent aspiration.13,15–18 Follow-up in published
studies was shorter than the present cohort (median
follow-up of four months). It is expected that
SAE rate (including migration and dysfunction) will
progressively increase with a longer follow-up.
Nevertheless, our adverse event rate, adapted to our
longer mean follow-up period (49 months), was lower
(Table 513,15–19).
Among these SAEs, BBS is defined as progressive
migration of the inner bumper of the PEG tube until
it becomes embedded in the stomach wall.20,21 BBS
occurred in two patients (7%) aged 60 and 68 years
old after a follow-up after PEG-J placement of 17
and 34 months, respectively. Endoscopic needle knife
excision21–23 was successfully performed (n¼ 2).
Adequate nurse care applied after PEG insertion and
continued during the follow-up could result in a lower
prevalence of BBS.21 Such prophylactic attitudes are
not yet described to prevent the other SAEs (migration,
ulcers, enteral fistulas, etc.). In this regard, we observed
that patients encountering SAEs had higher comorbid-
ities, suggesting that more fragile patients would be at
higher risk of SAEs. Recently, retrospective studies
comparing younger and older patients demonstrated
that PEG procedure-related adverse events and mortal-
ity were similar in both groups.24,25 In line with this, we
did not observe a statistical difference in terms of
median age between patients encountering adverse
events and those who did not. Our results suggest
that age is not a good indicator of vulnerability in
this Parkinson’s disease population. However, comor-
bidity score could be a surrogate of adverse event risk.
Indeed, we observed that patients who encountered
SAEs had a significantly higher CPS. The same trend
Figure 4. Coronal multiplanar CT reconstruction showing (a)
internal bumper migration into the duodenum and (b, c) multiple
jejunal fistulas caused by migration of the jejunal extension. This
severe adverse event occurred 14 months after percutaneous
endoscopic gastrostomy and jejunal tube (PEG-J) placement. The
patient presented to the emergency room with abdominal pain,
nausea and vomiting. The patient required surgical treatment with
intestinal resection and re-anastomosis; follow-up was favourable
but PEG-J had to be definitely removed.
Figure 3. Computed tomography showing extra-intestinal air
bubbles (arrows), following percutaneous endoscopic gastrostomy
and jejunal tube replacement (intestinal perforation). The patient
presented abdominal pain and was put on antibiotics and outcome
was uneventful.
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was observed using the CCI, without being statistically
significant. This could be explained by a lower sensitiv-
ity in Parkinson’s disease patients for the CCI in com-
parison with the CPS.26 Even if we demonstrated that
CPS could be used as a determinant risk factor, we still
observed a low median CPS of 11. Thus, we think that
more accurate comorbidity scores should be validated
to characterize this particular population.
Furthermore, in light of these results, comorbidity
scores could be used during the patient’s selection pro-
cess. As well, patients who encountered immediate
adverse events following PEG-J placement should be
more closely followed as it seems, from our results,
that they are more vulnerable to delayed SAEs.
In a recent study evaluating outcome and adverse
events of PEG utilization for long-term enteral feeding,
a SAE rate of 2.4% (during a mean follow-up period of
five months) has been reported.19 In fact, our rate per
month of SAEs related to PEG-J is nearly twice as high
in comparison with this reported rate per month related
to PEG (Table 5). This could be largely attributed to
the jejunal tube. Moreover, we think that jejunal tube
structure played a role in adverse event incidence. We
observed an increased rigidity of jejunal tubes in place
during longer periods of time and in patients develop-
ing a SAE. Rigid jejunal extension could potentially
cause intestinal wall erosion and progressive transmural
migration. Rigidity development could be linked with
the long-term infusion of the levodopa-carbidopa medi-
cation through the jejunal tube, which might deserve
improvements. Hence, an earlier systematic replace-
ment of the PEG-J could be proposed.
The small number of patients who withdrew from
therapy is encouraging, as demonstrated by 71% of
patients still on treatment on 1 April 2015. This could
be explained by a close follow-up and by the fact that
Belgian reimbursement criteria for levodopa-carbidopa
are restrictive, as an objective therapeutic effect needs
to be demonstrated. This results in a selection of
patients who are living at home with a significant
degree of autonomy and have no or only mild cognitive
impairment, making them less susceptible for
discontinuation.
Many options have been proposed to deliver medi-
cation and/or nutrition directly to the jejunum includ-
ing PEG-J, direct percutaneous endoscopic
jejunostomy (DPEJ), and (open and laparoscopic)





patients Treatment type Treatment modality
Duodenal ulcer 2/20 (10) 2 Endoscopy PPI and definitive or temporary (nine
days) J tube removal
Buried bumper syndrome 2/20 (10) 2 Endoscopy Needle knife excision
J-tube impaction in the jejunum 1/20 (5) 1 Endoscopy Endoscopic release with a guidewire
J-tube migration 6/20 (30) 5 Endoscopy J tube replacement
J-tube dysfunction 6/20 (30) 5
Leakage 1/20 (5) 1 Endoscopy J tube replacement
Kinking 1/20 (5) 1 J tube replacement
Clogging 4/20 (20) 3 Guidewire recanalization (2/4) and
replacement (2/4)
Covered duodenal perforation 1/20 (5) 1 Conservative Antibiotic (amoxicillin/clavulanic
acid, 2 g 3 times/day, i.v.)
Multiple jejunal fistulas 1/20 (5) 1 Surgery Intestinal resection
Infected intra-abdominal collection 1/20 (5) 1 Conservative Antibiotic (piperacillin-tazobactam,
4 g 4 times/day, i.v.)
SAE: severe adverse event





age, years p value
Severe AE 1 15 0.011 64 0.941
0 10 63
Immediate AE 1 12 0.020 66 0.620
0 8.5 63.5
Minor AE 1 10.5 0.978 68 0.267
0 11 63.5
Total population 11 64
AE: adverse event; CPS: Comorbidity–Polypharmacy Score
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surgical jejunostomies.14 Yet, no comparative study has
been performed to reveal which technique would have
the best outcome in fragile patients. Nevertheless, endo-
scopic techniques are favoured over surgery.14 PEG-J is
the most commonly performed method despite the fact
that it presents frequent J-tube migration and dysfunc-
tion.27,28 DPEJ could have been proposed bearing in
mind that it is a more stable jejunal access which
requires fewer interventions than PEG-J.17 However,
in two recent retrospective studies, the relatively low
placement success rate of DPEJ was confirmed,
mainly due to failure to identify the puncture site.28,29
Currently PEG-J is considered the enteral access of
choice for continuous levodopa-carbidopa delivery.
Our data confirm, however, the high incidence of
SAEs along the course of this treatment, related to
the PEG-J itself. While subject to all the limitations
of a retrospective case series, this report with a long
follow-up of four years is helpful in delineating the
risk–benefit ratio of PEG-J placement for levodopa-
carbidopa infusion in patients with Parkinson’s disease
and provides useful information to clinicians and
endoscopists. It is, to our knowledge, the largest
study which analysed global PEG-J management for
levodopa-carbidopa infusion from the endoscopist
point of view.
In conclusion, placement of a PEG-J tube for levo-
dopa-carbidopa jejunal treatment in patients with
advanced Parkinson’s disease is an effective technique
but which carries a high risk of adverse events, prob-
ably linked to the overall fragility of these patients and
to devices which would still benefit from improvements.
Patients should be fully informed of procedure-related
adverse events and should be followed up accordingly
in referral centres.
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